Altos Labs was founded in 2021 by Hans Bishop and Richard Klausner. Altos Labs has not publicly endorsed a plan to participate in an IPO.

Altos Labs is a biotech company with a focus on cellular rejuvenation programming to restore cell health and resilience. Per Forge data, the most recent funding for Altos Labs was in January 2021. Their total funding raised is $3 billion. Key investors include ARCH Venture Partners.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Altos Labs, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Altos Labs

Forge green plus iconForge green minus icon

What is Altos Labs's IPO price?

The IPO price for Altos Labs will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Altos Labs?

Altos Labs is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Altos Labs shares pre-IPO?

If you own Altos Labs pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Altos Labs a publicly traded company?

Altos Labs is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Altos Labs's funding to date?

Altos Labs has raised $2.62B to date.
Forge green plus iconForge green minus icon

When was Altos Labs founded?

Altos Labs was founded in 2021.
Forge green plus iconForge green minus icon

Did Jeff Bezos invest in Altos Labs?

Jeff Bezos invested in Altos Labs in 2022.

Forge green plus iconForge green minus icon

What does Altos Labs do?

Altos Labs is a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.

Forge green plus iconForge green minus icon

Who is the CEO of Altos Labs?

The CEO of Altos Labs is Hal Barron.

Who are Altos Labs's major investors?

Arch Venture Partners
Foresite Capital
Mubadala Investment Company

Altos Labs funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
2/14/2024

Series C

$1.5B raised $XXX.XX $XXX.XX
3/25/2022

Series B

$818.78MM raised $XXX.XX $XXX.XX
9/4/2021

Series A

$305.91MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.